BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Merck Sharp & Dohme  Ltd. submitted on 28 June 2006 an application for Marketing 
Authorisation to the European Medicines Agency (EMEA) for ADROVANCE, through the centralised 
procedure.   
The  legal  basis  for  this  application  refers  to  Article  10c  of  Directive  2001/83/EC,  as  amended  – 
relating to informed consent from the marketing authorisation holder, Merck Sharp & Dohme Ltd., for 
the authorised medicinal product FOSAVANCE (EU/1/05/310/001-005). 
Licensing status: 
The  initial  product,  FOSAVANCE,  has  been  given  a  Community  Marketing  Authorisation  on  
24 August 2005. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:   Ian Hudson 
Co-Rapporteur:  Josef Suko 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 28 June 2006. 
The procedure started on 21 July 2006.  
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  18 
September  2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 22 September 2006. 
The Rapporteur circulated an updated Assessment Report to all CHMP members on 13 October 
2006. 
The applicant provided on 17 October 2006 a letter of undertaking of the follow-up measures to 
be fulfilled post-authorisation. 
During  the  meeting  on  16-18  October  2006,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to ADROVANCE on 18 October 2006.  
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 4 January 2007. 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
